Activation of IL-17 signaling is observed in the pathogenesis of various autoimmune disorders, including rheumatoid arthritis, asthma, lupus, allograft rejection, anti-tumor immunity, psoriasis, and multiple sclerosis, and IL-17 inhibitors are being investigated as possible treatments for these disorders. Here, IL17A is linked to rheumatoid arthritis.